Shimadzu Expands into Biopharmaceuticals with Sepragen Partnership

Shimadzu Corporation has announced a strategic alliance with California-based Sepragen Corporation, marking an expansion into the biopharmaceutical sector. Effective November, Shimadzu will be the exclusive marketer and service provider for Sepragen’s bioprocess chromatography systems in Japan, South Korea, and Southeast Asia. This partnership aims to leverage the promising growth opportunities in the purification technologies used for vaccine and gene therapy drug manufacturing.

Founded in 1985, Sepragen Corporation is renowned for its advanced process chromatography solutions, notably its radial flow chromatography and automatic buffer preparation units. These technologies enhance the efficiency and productivity of biopharmaceutical purification, a crucial phase where impurities are removed to isolate the desired compound. The biopharmaceutical market is experiencing rapid expansion, with a double-digit annual growth rate, driven by rising demand for vaccines and gene therapies.

 However, scaling purification processes and analysing quality parameters remain challenging. Shimadzu, with its expertise in analytical and measuring instruments, offers solutions to these bottlenecks. This partnership marks Shimadzu’s commitment to delivering comprehensive solutions, from research to manufacturing, within the pharmaceutical landscape.

By collaborating with Sepragen, Shimadzu is expected to make significant strides in the biopharmaceutical industry, aligning with its vision to provide comprehensive solutions across the pharmaceutical sector. This partnership not only enhances Shimadzu’s product offerings but also its commitment to driving innovations that support development and stable manufacturing in the biopharmaceutical domain.

For the latest updates and in-depth insights into the world of Service Engineering, including breakthrough partnerships, industry trends, and regulatory news, contact Adam Tiberius today!